HOME




Wednesday, 8 September 2010
Novogen agrees to sell its Intellectual Property Portfolio to its subsidiary Marshall Edwards

More news

 





Back Print ASX Releases

Board changes at Novogen Limited

Novogen Limited (ASX:NRT; NVGN: Nasdaq) is pleased to announce the appointment of Mr William D Rueckert to its Board of Directors. 

The advantage for Novogen of Mr Rueckert becoming a director is that he is already familiar with the group, having been a Director for two years on the boards of subsidiaries, Glycotex and Marshall Edwards, and brings considerable US based commercial experience.

Mr Rueckert is the Managing Member of Oyster Management Group LLC and is a Director of Glycotex, Inc., an 83 per cent owned unlisted subsidiary of Novogen Limited.  Mr Rueckert was formerly a Director of Emergency Filtration Products, Inc., a public manufacturer and marketer of respiratory filtration devices, president and director of Eastern Capital Development, LLC since 1999, president and director of Rosow & Company, a private investment firm based in Connecticut since 1990, treasurer of Moore & Munger, Inc. a company with interests in the petroleum and resort development industries, from 1988 until 1990, and was president of United States Oil Company, a publicly traded oil exploration business, from 1981 to 1988.  Among his many civic associations, Mr Rueckert is director and president of the Cleveland H. Dodge Foundation, a private philanthropic organization in New York City and chairman of the Board of the Trustees of Teachers College, Columbia University.

Mr Rueckert has resigned as a director of Marshall Edwards Inc, the 72 per cent US subsidiary of Novogen Limited.

Welcoming Mr Rueckert to the Novogen board its Chairman, Philip Johnston, said his particular expertise and experience would bring additional strong commercial acumen to the Board and in particular his knowledge of all facets of the US capital markets.  His two years on the boards of Marshall Edwards and Glycotex have further equipped Mr Rueckert with a detailed understanding of the operations of the Novogen Group.

Novogen Limited also announces that Mr Peter Simpson will retire as a director prior to 30 June, 2009.

At Novogen’s AGM last year Mr Simpson, having been a Director for 15 years, indicated his intention to resign this year after a suitable replacement was found.

 
Top Print

 

 





About Novogen | Knowledge Base | Consumer Health | Pharmaceuticals | News | Investor Relations | Contact | Site Map
Copyright © 2010 Novogen The world leader in isoflavone research - with products including Promensil and Trinovin | Web Design by Newgency